Targeting the follicular lymphoma microenvironment through blockade of TNFα with etanercept

Leukemia and Lymphoma

Volumn 49, Issue 5, 2008, Pages 902-909

  Friedberg, Jonathan ^a   Jacobsen, Eric ^b   Neuberg, Donna ^b   Kutok, Jeffrey ^c   Munoz, Olivier ^b   Boussiotis, Vassiliki ^b   Reynolds, Hazel ^b   Fisher, David ^b   Szot, Agnieszka ^b   Van Den Abbeele, Annick ^b   Freedman, Arnold ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Approaches; Chemotherapeutic; Dendritic cell biology; Immunobiology; Lymphoma and Hodgkin disease

Indexed keywords

ETANERCEPT; FLUORODEOXYGLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FEMALE; FOLLICULAR DENDRITIC CELL; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INJECTION SITE REACTION; LABORATORY TEST; LYMPHOCYTOPENIA; MALE; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHINITIS; TREATMENT DURATION;

ADULT; AGED; DRUG DELIVERY SYSTEMS; DRUG MONITORING; HUMANS; IMMUNOGLOBULIN G; LYMPHOMA, FOLLICULAR; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, TUMOR NECROSIS FACTOR; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 46749084678     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801950033     Document Type: Article

References (30)

1. Armitage, J. O. and Weisenburger, D. D. (1998) New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol, 16, pp. 2780-2795.
2. Fisher, R. I., LeBlanc, M., Press, O. W., Maloney, D. G., Unger, J. M. and Miller, T. P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol, 23, pp. 8447-8452.
3. Petrasch, S., Stein, H., Kosco, M. H. and Brittinger, G. (1991) Follicular dendritic cells in non-Hodgkin lymphomas: Localisation, characterisation and pathophysiological aspects. Eur J Cancer, 27, pp. 1052-1056.
4. Petrasch, S., Kosco, M., Perez-Alvarez, C., Schmitz, J. and Brittinger, G. (1992) Proliferation of non-Hodgkin-lymphoma lymphocytes in vitro is dependent upon follicular dendritic cell interactions. Br J Haematol, 80, pp. 21-26.
5. Lindhout, E., Mevissen, M. L., Kwekkeboom, J., Tager, J. M. and de Groot, C. (1993) Direct evidence that human follicular dendritic cells (FDC) rescue germinal centre B cells from death by apoptosis. Clin Exp Immunol, 91, pp. 330-336.
6. Salles, G., Bienvenu, J., Bastion, Y., Barbier, Y., Doche, C. and Warzocha, K. (1996) Elevated circulating levels of TNFα and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br J Haematol, 93, pp. 352-359.
7. Gruss, H. J. and Dower, S. K. (1995) Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas. Blood, 85, pp. 3378-3404.
8. Culy, C. R. and Keating, G. M. (2002) Etanercept: An updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs, 62, pp. 2493-2537.
9. Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K. and Vardiman, J. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol, 17, pp. 3835-3849.
10. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, p. 1244.
11. Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O. and Lammertsma, A. A. (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer, 35, pp. 1773-1782.
12. Husson, H., Lugli, S. M., Ghia, P., Cardoso, A., Roth, A. and Brohmi, K. (2000) Functional effects of TNF and lymphotoxin α1β2 on FDC-like cells. Cell Immunol, 203, pp. 134-143.
13. Friedberg, J. W., Fischman, A., Neuberg, D., Kim, H., Takvorian, T. and Ng, A. K. (2004) FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison. Leuk Lymphoma, 45, pp. 85-92.
14. Lee, A. M., Clear, A. J., Calaminici, M., Davies, A. J., Jordan, S. and MacDougall, F. (2006) Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol, 24, pp. 5052-5059.
15. Hilchey, S. P., De, A., Rimsza, L. M., Bankert, R. B. and Bernstein, S. H. (2007) Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T Cells. J Immunol, 178, pp. 4051-4061.
16. Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D. and Chan, W. C. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med, 351, pp. 2159-2169.
17. Johnson, P. W., Watt, S. M., Betts, D. R., Davies, D., Jordan, S. and Norton, A. J. (1993) Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood, 82, pp. 1848-1857.
18. Freedman, A. S., Munro, J. M., Rice, G. E., Bevilacqua, M. P., Morimoto, C. and McIntyre, B. W. (1990) Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science, 249, pp. 1030-1033.
19. Anolik, J. H., Ravikumar, R., Barnard, J., Owen, T., Almudevar, A. and Milner, E. C. (2008) Cutting edge: Anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol, 180, pp. 688-692.
20. Ott, K., Weber, W. A., Lordick, F., Becker, K., Busch, R. and Herrmann, K. (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol, 24, pp. 4692-4698.
21. Wieder, H. A., Brucher, B. L., Zimmermann, F., Becker, K., Lordick, F. and Beer, A. (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol, 22, pp. 900-908.
22. Brown, S. L., Greene, M. H., Gershon, S. K., Edwards, E. T. and Braun, M. M. (2002) Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum, 46, pp. 3151-3158.
23. Wolfe, F. and Michaud, K. (2004) Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum, 50, pp. 1740-1751.
24. Geborek, P., Bladstrom, A., Turesson, C., Gulfe, A., Petersson, I. F. and Saxne, T. (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis, 64, pp. 699-703.
25. Hochberg, M. C., Lebwohl, M. G., Plevy, S. E., Hobbs, K. F. and Yocum, D. E. (2005) The benefit/risk profile of TNF-blocking agents: Findings of a consensus panel. Semin Arthritis Rheum, 34, pp. 819-836.
26. Tsimberidou, A. M., Giles, F. J., Duvic, M. and Kurzrock, R. (2004) Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol, 51, pp. 200-204.
27. Shih, T. and Lindley, C. (2006) Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther, 28, pp. 1779-1802.
28. Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H. and Dowlati, A. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 355, pp. 2542-2550.
29. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J. and Heim, W. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, pp. 2335-2342.
30. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J. and Topalian, S. L. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 349, pp. 427-434.